Shares of Cantel Medical Corp. (NYSE:CMD) have been given a consensus broker rating score of 2.50 (Hold) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Cantel Medical Corp.’s rating score has declined by 25% in the last three months as a result of a number of analysts’ ratings changes.

Zacks has also given Cantel Medical Corp. an industry rank of 161 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have recently commented on CMD shares. Zacks Investment Research upgraded Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical Corp. in a research note on Friday, September 1st. Finally, Sidoti upgraded Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a research note on Wednesday, August 2nd.

Cantel Medical Corp. (NYSE:CMD) opened at $98.28 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.49 and a current ratio of 2.41. Cantel Medical Corp. has a 52 week low of $69.21 and a 52 week high of $99.83. The firm has a market capitalization of $4,100.93, a price-to-earnings ratio of 47.25 and a beta of 1.23.

Cantel Medical Corp. (NYSE:CMD) last issued its quarterly earnings data on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.52 by $0.02. Cantel Medical Corp. had a return on equity of 17.60% and a net margin of 9.27%. The business had revenue of $205.50 million for the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical Corp.’s revenue for the quarter was up 14.8% on a year-over-year basis. equities research analysts anticipate that Cantel Medical Corp. will post 2.34 earnings per share for the current year.

The firm also recently announced a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Stockholders of record on Wednesday, January 17th will be paid a dividend of $0.085 per share. This represents a dividend yield of 0.17%. This is a boost from Cantel Medical Corp.’s previous Semi-Annual dividend of $0.07. The ex-dividend date is Tuesday, January 16th. Cantel Medical Corp.’s payout ratio is presently 8.19%.

TRADEMARK VIOLATION NOTICE: “Zacks: Cantel Medical Corp. (CMD) Receives Consensus Rating of “Hold” from Analysts” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/zacks-cantel-medical-corp-cmd-receives-consensus-rating-of-hold-from-analysts/1697355.html.

In other news, EVP Eric W. Nodiff sold 2,868 shares of Cantel Medical Corp. stock in a transaction on Friday, October 20th. The stock was sold at an average price of $97.55, for a total transaction of $279,773.40. Following the sale, the executive vice president now directly owns 39,102 shares in the company, valued at approximately $3,814,400.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George L. Fotiades sold 6,000 shares of Cantel Medical Corp. stock in a transaction on Friday, October 13th. The stock was sold at an average price of $95.23, for a total value of $571,380.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,368 shares of company stock worth $3,576,028 over the last quarter. Company insiders own 14.90% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Trexquant Investment LP purchased a new stake in Cantel Medical Corp. in the 3rd quarter worth about $349,000. JPMorgan Chase & Co. increased its holdings in Cantel Medical Corp. by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 37,480 shares of the company’s stock worth $3,408,000 after acquiring an additional 7,917 shares during the last quarter. Legal & General Group Plc increased its holdings in Cantel Medical Corp. by 3.1% in the 3rd quarter. Legal & General Group Plc now owns 71,989 shares of the company’s stock worth $6,774,000 after acquiring an additional 2,135 shares during the last quarter. Wade G W & Inc. purchased a new stake in Cantel Medical Corp. in the 3rd quarter worth about $247,000. Finally, American International Group Inc. increased its holdings in Cantel Medical Corp. by 5.4% in the 3rd quarter. American International Group Inc. now owns 28,684 shares of the company’s stock worth $2,701,000 after acquiring an additional 1,464 shares during the last quarter. 85.38% of the stock is owned by institutional investors.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Get a free copy of the Zacks research report on Cantel Medical Corp. (CMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.